Scotts Miracle-Gro shares are trading below both analyst price targets and an estimated fair value, even after recent gains. The most followed narrative pegs the stock as 58% overvalued with a fair value of $43.49, well below the recent close of $68.53. However, the current price-to-earnings ratio of 19.3 times sits below the US Chemicals industry average of 24.7 times and peer multiples of 50.6 times, though slightly above a fair ratio of 18.7 times. The company has outlined its GroForward 2030 sustainability plan in its 2026 Corporate Responsibility Report, while investors await upcoming third quarter results. Risks remain from cannabis exposure and potential pressure on consumer or grower spending.
Scotts Miracle-Gro CompanyArticle discusses analyst targets, fair value estimates, and P/E comparisons, but the narrative is mixed (58% overvalued vs. below industry average P/E).